Compare LYFT & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYFT | RGEN |
|---|---|---|
| Founded | 2007 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.6B |
| IPO Year | 2019 | 1995 |
| Metric | LYFT | RGEN |
|---|---|---|
| Price | $17.51 | $181.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 12 |
| Target Price | $20.07 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 12.0M | 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | 286.96 |
| EPS | 0.16 | ★ 0.24 |
| Revenue | ★ $6,316,261,000.00 | $141,236,000.00 |
| Revenue This Year | $17.33 | $14.30 |
| Revenue Next Year | $12.29 | $14.52 |
| P/E Ratio | ★ $108.75 | $751.21 |
| Revenue Growth | 9.16 | ★ 35.10 |
| 52 Week Low | $12.46 | $100.99 |
| 52 Week High | $25.54 | $188.73 |
| Indicator | LYFT | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 76.48 |
| Support Level | $12.93 | $156.65 |
| Resistance Level | $17.76 | N/A |
| Average True Range (ATR) | 0.69 | 6.79 |
| MACD | 0.02 | 1.81 |
| Stochastic Oscillator | 78.45 | 84.69 |
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.